menu
    • menu

    Company profile for Remix Therapeutics

    NEW Drugs in Dev: 1
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Just as an instrument can be tuned to create an entirely different sound, RNA transcripts can also be tuned in a multitude of ways, extending far beyond simply splicing out non-coding introns. Development of new molecular tools and the advent of next-generation, multi-omic disease datasets has given us better insight into RNA’s vast intricacies and unveiled new, exciting insights into how RNA is processed and dysregulated af...
    Just as an instrument can be tuned to create an entirely different sound, RNA transcripts can also be tuned in a multitude of ways, extending far beyond simply splicing out non-coding introns. Development of new molecular tools and the advent of next-generation, multi-omic disease datasets has given us better insight into RNA’s vast intricacies and unveiled new, exciting insights into how RNA is processed and dysregulated after transcription. By unlocking these tools and controlling RNA processing we can target the drivers of disease at their origin, affording rich therapeutic opportunities.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Remix TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    One Kendall Square, Building 200, Cambridge MA 02139
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.remixtx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/remix-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Remix Therapeutics Presents REM-422 Phase 1/2 Data at ASCO 2026
    Remix Therapeutics Presents REM-422 Phase 1/2 Data at ASCO 2026

    21 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/21/3299795/0/en/remix-therapeutics-announces-positive-data-from-phase-1-2-aria-study-of-first-in-class-myb-mrna-degrader-rem-422-in-patients-with-adenoid-cystic-carcinoma-acc-at-the-american-socie.html

    GLOBENEWSWIRE
    21 May 2026
    Share Share
    Remix Therapeutics Presents REM-422 Phase 1/2 ARIA Trial Results
    Remix Therapeutics Presents REM-422 Phase 1/2 ARIA Trial Results

    21 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/21/3278198/0/en/remix-therapeutics-announces-oral-presentation-of-first-in-class-small-molecule-myb-mrna-degrader-rem-422-phase-1-2-aria-trial-results-at-the-2026-american-society-of-clinical-onco.html

    GLOBENEWSWIRE
    21 Apr 2026
    Share Share
    Remix Therapeutics Granted FDA Fast Track Designation for REM-422
    Remix Therapeutics Granted FDA Fast Track Designation for REM-422

    19 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/19/3258865/0/en/Remix-Therapeutics-Granted-FDA-Fast-Track-Designation-for-REM-422-for-the-Treatment-of-Recurrent-Metastatic-or-Unresectable-Adenoid-Cystic-Carcinoma.html

    GLOBENEWSWIRE
    19 Mar 2026
    Share Share
    Remix Therapeutics Names Mythili Koneru as Chief Medical Officer
    Remix Therapeutics Names Mythili Koneru as Chief Medical Officer

    06 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/06/3213556/0/en/Remix-Therapeutics-Appoints-Mythili-Koneru-MD-PhD-as-Chief-Medical-Officer.html

    GLOBENEWSWIRE
    06 Jan 2026
    Share Share
    Remix Therapeutics To Present at Guggenheim Health Conference
    Remix Therapeutics To Present at Guggenheim Health Conference

    03 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/03/3179174/0/en/Remix-Therapeutics-to-Present-at-Guggenheim-Second-Annual-Healthcare-Innovation-Conference.html

    GLOBENEWSWIRE
    03 Nov 2025
    Share Share
    Remix Therapeutics Reveals Encouraging Phase 1 Data For REM-422
    Remix Therapeutics Reveals Encouraging Phase 1 Data For REM-422

    24 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/24/3172910/0/en/Remix-Therapeutics-Announces-Positive-Preliminary-Data-from-Phase-1-Study-of-REM-422-in-Patients-with-Adenoid-Cystic-Carcinoma-at-the-2025-AACR-NCI-EORTC-International-Conference-o.html

    GLOBENEWSWIRE
    24 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search